(Q35177665)

6 August 2017

1 reference

title

Insulin glargine: a systematic review of a long-acting insulin analogue (English)

1 reference

6 August 2017

1 reference

1 reference

1 reference

Fei Wang

1

1 reference

6 August 2017

Jana M Carabino

series ordinal

2

1 reference

6 August 2017

Cunegundo M Vergara

series ordinal

3

1 reference

6 August 2017

publication date

1 June 2003

1 reference

6 August 2017

published in

Clinical Therapeutics

1 reference

6 August 2017

volume

25

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

1541-77, discussion 1539-40

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

The physiologic replacement of insulin. An elusive goal

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Physiological insulin replacement in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Intensive treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

The action profiles of human NPH insulin preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Recombinant DNA technology in the treatment of diabetes: insulin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Insulin glargine: a new basal insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Insulin glargine: the first clinically useful extended-action insulin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

1 reference

7 January 2021

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Why some cases of retinopathy worsen when diabetic control improves

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Safety of insulin glargine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

Use of insulin glargine during pregnancy in a type 1 diabetic woman

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980156-X

7 January 2021

10.1016/S0149-2918(03)80156-X

Identifiers

DOI

1 reference

6 August 2017

1 reference